Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans increased its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 54.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,505,753 shares of the company's stock after acquiring an additional 532,040 shares during the period. Thrivent Financial for Lutherans owned approximately 2.52% of Twist Bioscience worth $69,972,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in TWST. Cibc World Markets Corp acquired a new position in shares of Twist Bioscience in the 4th quarter valued at $253,000. Swiss National Bank lifted its position in Twist Bioscience by 1.1% in the fourth quarter. Swiss National Bank now owns 115,200 shares of the company's stock valued at $5,353,000 after buying an additional 1,200 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Twist Bioscience by 59.6% during the fourth quarter. Farther Finance Advisors LLC now owns 5,429 shares of the company's stock worth $252,000 after buying an additional 2,028 shares during the period. Wealthfront Advisers LLC acquired a new stake in shares of Twist Bioscience during the fourth quarter valued at about $209,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Twist Bioscience by 5.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,064 shares of the company's stock valued at $793,000 after acquiring an additional 821 shares during the period.

Twist Bioscience Stock Up 2.0 %

NASDAQ TWST traded up $0.84 during trading hours on Friday, hitting $42.89. 1,319,967 shares of the company were exchanged, compared to its average volume of 925,409. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of -12.69 and a beta of 2.15. The company has a 50 day moving average of $45.40 and a two-hundred day moving average of $45.23. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period in the prior year, the firm earned ($0.75) earnings per share. The business's quarterly revenue was up 24.1% compared to the same quarter last year. Equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Activity

In other Twist Bioscience news, insider Dennis Cho sold 806 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the sale, the insider now directly owns 112,221 shares in the company, valued at $5,538,106.35. This trade represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares of the company's stock, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 31,552 shares of company stock worth $1,500,289. 3.01% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of research analyst reports. TD Cowen reaffirmed a "buy" rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird raised their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective for the company. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $54.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.